The Survival Implications of Bone Mineral Loss

In a Town Hall discussion,  “Ablating Testosterone in Prostate Cancer and the Concomitant Negative Effects”,  Fred Saad, MD,  FRCS, Director of Urologic Oncology, Professor of Surgery/Urology, U of M Chair in Prostate Cancer; University of Montreal discussed the negative effects that bone loss resulting from hormone therapy (ADT)  poses to our life expectancy. His over [...]

On the Horizon – Denosumab, An alternative To Zometa To Protect Bones While Treating Advanced Prostate Cancer

Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events Amgen (NASDAQ: AMGN) has announced positive results from a Phase III head-to-head trial evaluating denosumab administered subcutaneously, versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion. Currently Zometa is the FDA approved treatment for bone [...]

By |2017-10-19T10:54:43-04:00August 9th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Meta